Go to deals
Healthcare

Dr. Willmar Schwabe India has acquired Sanat Products Ltd.

Dr. Willmar Schwabe India, a subsidiary of the German Dr. Willmar Schwabe Group, has acquired Sanat Products Ltd.

Dr. Willmar Schwabe India is engaged in the manufacturing of homeopathic medicines, herbal medicines, specialty formulations and cosmetic products. Dr. Willmar Schwabe Group, based in Germany, is present on five continents. The Schwabe Group comprises several different affiliated companies in the pharmaceutical and health industry. All of the companies within the group focus on plants as the basis for developing their products.

Founded in 1984, Sanat Products Ltd. is a leading manufacturer, supplier and exporter of herbal extracts, ethical products and consumer products. The herbal extracts division (HED) is engaged in the extracting and marketing of standardized herbal extracts to meet the needs of the pharmaceutical, cosmetic, ayurvedic and food industries. The ethical products division (EPD) – prescription-based drugs – offers more than 25 products across a therapeutic mix covering significant chronic and acute segments. These products include dental, oncology, gynecology, diabetes, cardiovascular diseases, dermatology and pain management. The consumer products division (CPD) offers nutraceuticals under brands such as Sunova Bioslim, Sunova Spirulina, Sunova Dr. Shugar, Sunova Curcumin, Uplat and Turmix.

Oaklins’ team in India advised the buyer in this transaction.

Service
M&A buy-side
Parties

Talk to the deal team

 Parag  Khadgi

Parag Khadgi

Partner

Mumbai, India
Oaklins YES Securities

Related deals

Global Media Santé has been acquired by SFP Expansion
Private Equity | Healthcare | TMT

Global Media Santé has been acquired by SFP Expansion

Global Media Santé’s CEO, Alain Trébucq, and Apax Partners have sold the company to SFP Expansion Group.

Learn more
Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate
Healthcare

Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate

Synairgen plc has completed its oversubscribed equity fundraising to raise US$114 million to fund a phase III trial for 900 patients for the effects of its SNG001 drug on patients with COVID-19. In addition, the raise will be used to scale up manufacturing and device activities.

Learn more
Westminster Homecare has been acquired by Care at Home
Healthcare

Westminster Homecare has been acquired by Care at Home

The private shareholders of Westminster Homecare Ltd. have sold the company to Care at Home Services (South East) Ltd.

Learn more